EXPERT OPINIONS
We spoke with several industry experts to validate our research.
Chandrabali Ghose
David Pride MD PhD
Dr. Pride is the Director of the Clinical Molecular Microbiology Laboratory and the Associate Director of the Microbiology Laboratory. He has been working to understand interactions between phages and their host bacteria for phage therapy.
"Bacteriophage therapy is an arms race. If a sustainable alternative like lysin therapy can be developed, it will be the future towards solving anti-microbial resistance."
Kevin Brown
PhD candidate at Yale University, working at the Turner Lab. He specializes in analyzing the synergy between antibiotics and bacteriophages.
"This is a very interesting concept and one that is not explored often. If lysins can be tuned to be as effective and scalable as current therapeutics, this could be promising."
Chief Executive Officer of Bioharmony Therapeutics, a start-up focusing on developing lysin-based therapies for Gram-Negative bacteria.
"One possible pathway lysin therapy could follow is a readily available, at-home antibiotic alternative. LyseDevice offers an interesting step towards this vision."